Management of Renal Cell Carcinoma
To offer optimal care to patients with RCC, clinicians must have a deep understanding of the key trial results and know how to best contextualize evidence to optimize considerations at key decision points along the RCC treatment continuum.
Category
- Kidney Cancer
Format
- Recorded Webcast
Credits
- 0.75 AAPA Category 1 CME credit
- 0.75 ACPE contact hours
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC contact hours
- 0.75 Participation
Cost $0.00
Updates in the Treatment of Metastatic Urothelial Cancer
Systemic therapy options for advanced bladder cancer continue to expand. The approvals of new therapies or combinations of therapies and emerging clinical trial data continue to impact the treatment landscape, and education on the topic would be valuable to help clinicians stay up to date with the latest research
Category
- Bladder Cancer
Format
- Recorded Webcast
Credits
- 0.75 AAPA Category 1 CME credit
- 0.75 ACPE contact hours
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC contact hours
- 0.75 Participation
Cost $0.00
Risk Stratification and Selection of Management Strategy for Localized Prostate Cancer
For some patients with localized prostate cancer, the treatment approach is determined by patient and disease characteristics. For others, advanced risk stratification with gene expression profiling or AI-derived digital histopathology biomarkers can help identify those who may derive greater or lesser absolute benefit from a given treatment, thus informing treatment decisions and reducing the chances of over- or under-treatment.
Category
- Acute Myelogenous Leukemia
Format
- Recorded Webcast
Credits
- 0.75 AAPA Category 1 CME credit
- 0.75 ACPE contact hours
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC contact hours
- 0.75 Participation
Cost $0.00
Updates to the Management of Cutaneous Melanoma
Despite recent advances in immunotherapies and targeted therapies for patients with advanced melanoma, treatment options are at times limited by the availability of reliable molecular markers, development of drug resistance, and the need for better early diagnosis. An overview of current challenges facing this patient population, as well as an in-depth analysis of treatment modalities, will benefit clinicians in selecting treatment options for patients with melanoma.
Category
- Melanoma
Format
- Recorded Webcast
Credits
- 0.75 AAPA Category 1 CME credit
- 0.75 ACPE contact hours
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC contact hours
- 0.75 Participation
Cost $0.00
Updates to the Management of Endometrial Cancer
Comprehensive knowledge in this topic will guide practitioners in providing appropriate treatment to improve patient outcomes.
Category
- Gynecologic Cancers
Format
- Recorded Webcast
Credits
- 0.75 AAPA Category 1 CME credit
- 0.75 ACPE contact hours
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC contact hours
- 0.75 Participation
Cost $0.00
Basal Cell and Squamous Cell Skin Cancers: NCCN Guidelines® Updates Based on Risk Status
While the prognosis for patients with squamous and basal cell skin cancer is generally good, current treatment recommendations are limited by the risk status classifications and associated available treatment options. There are subsets of patients who are prone to recurrence or regional and distant metastasis. Awareness of these disease features is crucial to identifying such patients and performing the appropriate treatment, especially as new regimens become available.
Category
- Skin Cancers
Format
- Recorded Webcast
Credits
- 0.75 AAPA Category 1 CME credit
- 0.75 ACPE contact hours
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC contact hours
- 0.75 Participation
Cost $0.00
Acute Myeloid Leukemia: Role of FLT3 Inhibitors After Allogeneic Hematopoietic Cell Transplantation
It is important for clinicians to be aware of the emerging evidence supporting the use of FLT3 inhibitors as a predictor of post-transplant relapse in patients with AML.
Category
- Acute Myelogenous Leukemia
Format
- Recorded Webcast
Credits
- 0.75 AAPA Category 1 CME credit
- 0.75 ACPE contact hours
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC contact hours
- 0.75 Participation
Cost $0.00
Plenary Session - Promising Practices to Reduce the Impact of Drug Shortages on Cancer Care
Cancer drug shortages have had a significant impact on clinical practice with much confusion around how to appropriately manage care of patients with cancer in the midst of a drug shortage. You can benefit by learning what you can do both in your practice and in your advocacy to advance short-term and long-term solutions.
Category
- Best Practices
Format
- Recorded Webcast
Credits
- 1.25 AAPA Category 1 CME credit
- 1.25 ACPE contact hours
- 1.25 AMA PRA Category 1 Credit™
- 1.25 ANCC contact hours
- 1.25 ASWB continuing education credit
- 1.25 Participation
Cost $0.00
Psychotherapeutic Strategies and Pharmacotherapy Options for Addressing Distress in Cancer Patients
Many health care professionals have had limited education on supportive care topics and have learned on the job. The guidelines and literature continue to advance supportive oncology care.
Category
- Distress Management
- Supportive Care Topics
Format
- Recorded Webcast
Credits
- 0.75 AAPA Category 1 CME credit
- 0.75 ACPE contact hours
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC contact hours
- 0.75 Participation
Cost $0.00
Integrative Medicine and the Cancer Patient
Many health care professionals have had limited education on supportive care topics and have learned on the job. The guidelines and literature continue to advance supportive oncology care.
Category
- Supportive Care Topics
- Survivorship
Format
- Recorded Webcast
Credits
- 0.50 AAPA Category 1 CME credit
- 0.50 ACPE contact hours
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC contact hours
- 0.50 Participation
Cost $0.00